Calliditas Therapeutics AB (LC8.BE)
| Previous close | 9.79 |
| Open | 9.84 |
| Bid | 10.78 x 0 |
| Ask | 11.06 x 0 |
| Day's range | 9.84 - 11.17 |
| 52-week range | 7.03 - 12.94 |
| Volume | |
| Avg. volume | 21 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Exploring Three Swedish Growth Companies With High Insider Ownership On The Swedish Exchange
As global markets show signs of resilience, with indices like the S&P 500 nearing record highs, Sweden's market landscape presents a unique opportunity for investors interested in growth companies with high insider ownership. Such stocks often indicate a strong alignment between company management and shareholder interests, potentially offering stability and confidence during fluctuating market conditions.
- Zacks
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
